Neelima Chintapalli, MD
Hematology & Oncology · Bossier City, LANPI 1013108141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,620 and has fallen 94.1% since, to $96 in 2025. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 254 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$610
- Johnson & Johnson$381
- Merck$283
- Pfizer$268
- Pharmacyclics LLC, An Abbvie Company$254
- E.r. Squibb & Sons, L.L.C.$218
- plus $2K from 35 others
Across 45 payments — averaging $5672.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$198K
- AstraZeneca$22K
- Incyte Corporation$20K
- Novocure Inc.$15K
- Helsinn Healthcare SA$127
- Astrazeneca UK Limited$8
What the payments were for
- Food & beverage$3,64593%
- Education$2797%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $610 |
| Johnson & Johnson(2 entities) | 22 | $381 |
| Merck | 20 | $283 |
| Pfizer | 24 | $268 |
| Pharmacyclics LLC, An Abbvie Company | 13 | $254 |
| E.r. Squibb & Sons, L.L.C. | 21 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $193 |
| Amgen | 11 | $169 |
| Daiichi Sankyo Inc. | 7 | $159 |
| Bristol Myers Squibb | 10 | $146 |
| Gilead(2 entities) | 7 | $116 |
| AstraZeneca(2 entities) | 8 | $113 |
| Genentech USA, Inc. | 7 | $91 |
| AbbVie | 4 | $82 |
| Beigene USA, Inc. | 3 | $72 |
| Sanofi | 3 | $55 |
| Exelixis Inc. | 3 | $55 |
| Sobi, Inc | 3 | $54 |
| Astellas Pharma US Inc | 4 | $53 |
| Incyte Corporation | 3 | $53 |
| Tempus AI, Inc | 2 | $48 |
| Bayer | 3 | $48 |
| Eisai Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $33 |
| ADC Therapeutics America, Inc. | 2 | $32 |
| GSK | 2 | $29 |
| Puma Biotechnology, Inc. | 2 | $27 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Inari Medical, Inc. | 1 | $22 |
| Mylan Institutional Inc. | 1 | $21 |
| Adaptive Biotechnologies Corporation | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $18 |
| Array Biopharma Inc | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| CTI Biopharma Corp. | 1 | $16 |
| Tesaro, Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VELCADE$107
How this compares
$3,925 in reported general payments places this provider in the 45th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 27 | $369,169 |
| IbrancePalbociclib | 21 | $333,305 |
| Pazopanib Hcl | 12 | $129,871 |
| Lenalidomide | 13 | $112,396 |
| EliquisApixaban | 43 | $30,741 |
| Exemestane | 59 | $6,828 |
| Letrozole | 279 | $4,580 |
| Anastrozole | 74 | $1,696 |
| Tamoxifen Citrate | 60 | $1,489 |
| Hydroxyurea | 32 | $896 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $873 |
| Gabapentin | 35 | $489 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $358 |
| Ondansetron Hcl | 23 | $258 |
| Acyclovir | 21 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $72 | $369,16927 claims |
| PfizerIbrance, Eliquis | $268 | $364,04664 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $11 | $14921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Bossier City
- Hana SafahBaton Rouge$2M
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Nakhle SabaBaton Rouge$842K
- Marc MatranaNew Orleans$757K
- Prakash PeddiShreveport$405K
- Sanjay JunejaBaton Rouge$346K
- Lingling duNew Orleans$173K
- Kamran ShahidLake Charles$155K
- Kevin GallagherShreveport$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.